A Phase I Study of Fludarabine, Cytarabine, and Oxaliplatin in Patients with Relapsed or Refractory Acute Myeloid Leukemia

PURPOSE: The combination of cytarabine and fludarabine was associated with superior clinical outcomes compared to high-dose cytarabine in relapse acute myeloid leukemia (AML). We conducted a phase I study combining oxaliplatin with cytarabine and fludarabine for patients with relapsed or refractory...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Lymphoma Myeloma Leuk
Autors principals: Tsimberidou, Apostolia-Maria, Keating, Michael J., Jabbour, Elias J, Ravandi-Kashani, Farhad, O'Brien, Susan, Estey, Elihu, Bekele, Neby, Plunkett, William K., Kantarjian, Hagop, Borthakur, Gautam
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4387892/
https://ncbi.nlm.nih.gov/pubmed/24637132
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2014.01.009
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars